HBM Holdings (HBM Holdings) FCF Margin % : -45.07% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is HBM Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. HBM Holdings's Free Cash Flow for the six months ended in Dec. 2023 was $-21.86 Mil. HBM Holdings's Revenue for the six months ended in Dec. 2023 was $48.51 Mil. Therefore, HBM Holdings's FCF Margin % for the quarter that ended in Dec. 2023 was -45.07%.

As of today, HBM Holdings's current FCF Yield % is -15.95%.

The historical rank and industry rank for HBM Holdings's FCF Margin % or its related term are showing as below:

HBMHF' s FCF Margin % Range Over the Past 10 Years
Min: -3245.39 Med: -693.53 Max: -24.14
Current: -24.14

During the past 6 years, the highest FCF Margin % of HBM Holdings was -24.14%. The lowest was -3245.39%. And the median was -693.53%.

HBMHF's FCF Margin % is ranked better than
68.2% of 1041 companies
in the Biotechnology industry
Industry Median: -145.04 vs HBMHF: -24.14

HBM Holdings FCF Margin % Historical Data

The historical data trend for HBM Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HBM Holdings FCF Margin % Chart

HBM Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,095.85

-255.12

-3,245.38

-291.21

-24.14

HBM Holdings Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial						-3,269.32	-195.12	-494.97	0.63	-45.07

Competitive Comparison of HBM Holdings's FCF Margin %

For the Biotechnology subindustry, HBM Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HBM Holdings's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HBM Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where HBM Holdings's FCF Margin % falls into.

HBM Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

HBM Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-21.602	/	89.502
	=	-24.14 %

HBM Holdings's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-21.862	/	48.506
	=	-45.07 %

HBM Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of HBM Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

HBM Holdings (HBM Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HBM Holdings Ltd (OTCPK:HBMHF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

02142:Hong Kong

Address

420 Fenglin Road, 12th Floor, Tower A, Fenglin International Plaza Phase II, Xuhui District, Shanghai, CHN, 200032

Website

https://www.harbourbiomed.com

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. Majority of revenue is generated from Europe.

HBM Holdings (HBM Holdings) Headlines

From GuruFocus

Harbour BioMed Announces Positive Profit Alert

By PRNewswire • 01-19-2024